Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.
You may also be interested in...
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.